Physician profile
Timothy F Simpson
NPI 1396187696
$12,678.85
in general payments reported to CMS, 2019-2025
17 companies · $775 in 2025
The $775 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $6,117 · 2022: $814 · 2023: $3,359 · 2024: $1,613 · 2025: $775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,203 · Travel and Lodging: $1,413 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,203.05 |
| Travel and Lodging | $1,412.69 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,132.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,495.84 | 2021-2024 | Optis, Xience Skypoint, Dragonfly Opstar |
| Biotronik INC. | $3,720.91 | 2021 | |
| Abiomed | $1,359.16 | 2022-2025 | Impella |
| Edwards Lifesciences Corporation | $1,132.00 | 2023 | Pascal |
| Boston Scientific Corporation | $596.52 | 2021-2025 | Rotapro, Avvigo Guidance System, Synergy |
| Medtronic, INC. | $524.48 | 2021-2022 | |
| Shockwave Medical, INC | $519.97 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| E.R. Squibb & Sons, L.L.C. | $124.76 | 2023-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $27.55 | 2023 | Lifevest |
| Heartflow, INC. | $27.02 | 2025 | |
| Pfizer INC. | $26.93 | 2025 | |
| Cvrx, INC. | $24.97 | 2024 | Barostim Neo System |
| Cagent Vascular INC | $24.62 | 2025 | Serrantor |
| Astrazeneca Pharmaceuticals LP | $23.08 | 2024 | |
| Merck Sharp & Dohme LLC | $21.97 | 2023 | Verquvo |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $21.07 | 2024 | Ozempic |
| Penumbra, INC. | $8.00 | 2023 | Indigo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Simpson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.